Supplements in the European Union: An Analysis of Health Claims Related to Articular Joint Health
Journal Title: European Journal of Nutrition & Food Safety - Year 2016, Vol 6, Issue 1
Abstract
In the European Union, amino acids, enzymes, pre- and probiotics, essential fatty acids, botanicals and botanical extracts and miscellaneous bioactive substances can be marketed as food supplements (FS). Food supplements that are meant to benefit human health contain claims on their label stating their benefits. Since 2007, health claims made on FS, are prohibited unless they are authorized and included in the EU Register of Nutrition and Health Claims on Food (the EU Register), in accordance with the requirements of Regulation (EC) nº 1924/2006. Aims: This manuscript reviews the evidence required to support health claims made on FS considering the legal framework of these foodstuffs and, as a case study, analyses the health claims on articular joint health included in the EU Register. The EFSA scientific opinions related to those health claims have also been considered. In EU, some botanicals and miscellaneous bioactive substances can be marketed as medicinal or as food supplements. The regulatory issues on botanicals and the debate on how to create a regulatory framework for botanicals is mentioned. Results: By April 2015, 77 functional health claims on joints health were included in the EU Register. The status of all these claims was non-authorised. The great majority were Article 13.1 claims (91%). All functional claims related to articular joints function were made on target functional ingredients, mainly other substances that could be used in the manufacturing of FS. Human trials conducted in diseased population were the main statement from EFSA for the non-approval of the health claims on articular joints. Criteria and more guidance addressing methodological issues on human trials would benefit future applications and scientific research. Conclusion: Legal issues regarding other substances than vitamins and minerals, namely botanical ingredients should also be taken in account in future FS health claims on articular joints. On this subject, efforts to improve the existing regulatory framework, namely with regard to botanicals products could also benefit future FS health claims.
Authors and Affiliations
Madalena Bettencourt-Câmara, Bruno Sepodes, Rosário Bronze, Maria-Eduardo Figueira
Risk Assessments of Cyclamate, Saccharin, Neohesperidine DC, Steviol Glycosides and Neotamefrom Soft Drinks, “Saft” and Nectar
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM), Panel on Food Additives, Flavourings, Processing Aids, Materials in Contact with Food and Cosmetics, has at the request of the...
Selenium in Healthy Individuals in Mato Grosso do Sul State, Brazil
The aim of the present research was to assess plasma selenium concentrations in healthy individuals, in the State of Mato Grosso do Sul, Brazil, as part of the mapping of the Brazilians states. Selenium levels were measu...
The Nordic Monitoring of Diet, Physical Activity, Smoking, Alcohol and Overweight: 2011-2014
Background: The Nordic Plan of Action for better health and quality of life has been put forward by the Nordic Council of Ministers with the aim of reducing unhealthy lifestyles and overweight in the Nordic countries. Mo...
Chemical Sensitivity in the Elderly: Lessons Learned from Micronutrient Consumption in the Dutch Elderly Population
A food consumption survey in the Dutch elderly population (51-69 years of age) showed an increased trend in micronutrient supplement intake (36.4%; 120/347 participants). Because data on chemical sensitivity in the elder...
Assessment of Probiotics in Infant Formula and Cereal Based Baby Foods Containing Bifidobacterium lactis Bb12– Update 2014
“Assessment of benefits and risks of probiotics in processed cereal-based baby foods supplemented Bifidobacteriumn lactis Bb12” from 2010 answered a request from the Norwegian Food Safety Authority focusing on the age gr...